



Corres. and Mail
BOX AF

IFW
AF
1632

**RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1632
PATENT**
Customer No. 22,852
Attorney Docket No. 07680.0019

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
David MEEKER et al.) Group Art Unit: 1632
)
Application No.: 09/884,526) Examiner: S. Chen
)
Filed: June 19, 2001)
)
For: COMBINATION ENZYME)
REPLACEMENT, GENE THERAPY) **MAIL STOP: AF**
AND SMALL MOLECULE THERAPY)
FOR LYSOSOMAL STORAGE)
DISEASES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

TRANSMITTAL LETTER

Enclosed is a reply to the Final Office Action of February 18, 2004.

The claims are calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	7	-	11	0	x \$ 18	\$ 0
Indep.	1	-	1	0	x \$ 86	0
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$290	
Subtotal						\$
Reduction by ½ if small entity						-
TOTAL						\$ 0

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: May 17, 2004

By: E. Stewart Mittler
E. Stewart Mittler
Reg. No. 50,316



RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1632
PATENT
Customer No. 22,852
Attorney Docket No. 07680.0019-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
David MEEKER et al.) Group Art Unit: 1632
Application No.: 09/884,526) Examiner: S. Chen
Filed: June 19, 2001)
For: COMBINATION ENZYME)
REPLACEMENT, GENE) **MAIL STOP: AF**
THERAPY AND SMALL)
MOLECULE THERAPY FOR)
LYSOSOMAL STORAGE)
DISEASES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE AFTER FINAL UNDER 37 C.F.R. § 1.116

This paper is filed in reply to the Final Office Action dated February 18, 2004.
Applicants respectfully request reconsideration of this application in view of the following
amendments and remarks.

Amendments to the claims are reflected in the list of claims which begins on
page 2 of this paper.

Remarks begin on page 4 of this paper.